Problemi speciali
Convulsioni da PRESsione alta
Seizures in children with high blood pressure
R. Masetti, L. Ronchini, S. Riolo, F. Guida, I. Corsini, F. Carfagnini, F. Toni, D.M. Cordelli, A. Pession
Maggio 2019 - pagg. 297 -302
Abstract
Background - PRES (posterior reversible encephalopathy syndrome) is a clinical-radiological
entity characterised by a combination of neurological signs and symptoms and neuroradiological
alterations like subcortical and cortical vasogenic oedema that is bilateral
and symmetric and mainly involves the posteriors regions of cerebral hemispheres. Currently,
two theories exist about the pathophysiology of PRES; these theories identify arterial
hypertension and endothelial injury induced by an inflammatory process or immune
disorders as trigger factors of PRES. The signs and symptoms associated with PRES are
also common to other diseases of CNS, like ischemic or haemorrhagic events, infections,
neoplasia, metabolic diseases and epilepsy. These diseases have to be considered in the
differential diagnosis process. PRES is associated with a wide range of clinical conditions,
namely transplantations, immunosuppressive therapy, chemotherapy, autoimmune
diseases, infections and hypertension. As these groups of patients are more predisposed
to the onset of PRES, the encephalopathy should be taken into consideration and the right
exams should be prescribed in order to diagnose it. In this case brain MRI represents the
gold standard for the diagnosis. PRES is generally a reversible and benign condition, nevertheless
severe complications with poor clinical outcomes can occur.
Methods - The paper describes PRES peculiar aspects including a curios clinical case of PRES associated to a massive consumption of glycyrrhizic acid coming from liquorice sweets that Paolo (a 10- year-old boy) had been eating in high quantity every day since 4 months, unaware that his blood pressure would have increased until the onset of an encephalopathy that luckily had been solved without permanent outcomes.
Conclusion - It is essential to know patients categories that are at high risk of encephalopathy and suspect PRES at an early stage to start an appropriate treatment and avoid severe complications.
Methods - The paper describes PRES peculiar aspects including a curios clinical case of PRES associated to a massive consumption of glycyrrhizic acid coming from liquorice sweets that Paolo (a 10- year-old boy) had been eating in high quantity every day since 4 months, unaware that his blood pressure would have increased until the onset of an encephalopathy that luckily had been solved without permanent outcomes.
Conclusion - It is essential to know patients categories that are at high risk of encephalopathy and suspect PRES at an early stage to start an appropriate treatment and avoid severe complications.
Classificazione MeSH
Contenuto riservato
Per leggere l'articolo completo è necessario effettuare il login.
Non sei ancora registrato? Registrati
Bibliografia
PRES in children undergoing hematopoietic
stem cell or solid organ transplantation. Pediatrics
2015;135(5):890-901.
2. Bartynski WS. Posterior reversible encephalopathy
syndrome, part 2: controversies
surrounding pathophysiology of vasogenic
edema. Am J Neuroradiol 2008;29(6):
1043-9.
3. Bartynski WS. Posterior reversible encephalopathy
syndrome, part 1: fundamental
imaging and clinical features. AJNR Am J
Neuroradiol. 2008;29:1036-42.
4. Bartynski WS, Boardman JF. Distinct imaging
patterns and lesion distribution in posterior
reversible encephalopathy syndrome.
AJNR Am J Neuroradiol 2007;28:1320-7.
5. Hinchey J, Chaves C, Appignani B, et al. A
reversible posterior leukoencephalopathy
syndrome. N Engl J Med 1996;334(8):494-
500.
6. Provenzale JM, Graham ML. Reversible
leukoencephalopathy associated with graftversus-
host disease: MR findings. AJNR Am
J Neuroradiol 1996;17(7):1290-4.
7. Bartynski WS, Zeigler ZR, Shadduck RK,
Lister J. Pretransplantation conditioning influence
on the occurrence of cyclosporine or
FK-506 neurotoxicity in allogeneic bone marrow
transplantation. AJNR Am J Neuroradiol
2004;25:261-9.
8. Barbas AS, Rege AS, Castleberry AW, et al.
Posterior reversible encephalopathy syndrome
independently associated with tacrolimus
and sirolimus after multivisceral transplantation.
Am J Transplant 2013;13(3):808-10.
9. McKinney AM, Short J, Truwit CL, et al.
Posterior reversible encephalopathy syndroment
and imaging findings. AJR Am J Roentgenol
2007;189(4):904-12.
10. Casey SO, Sampaio RC, Michel E, Truwit
CL. Posterior reversible encephalopathy syndrome:
utility of fluid-attenuated inversion recovery
MR imaging in the detection of cortical
and subcortical lesions. AJNR Am J Neuroradiol
2000;21:1199-206.
11. Ay H, Buonanno F, Schaefer PW. Posterior
leukoencephalopathy without severe hypertension
- utility of diffusion-weighted MRI.
Neurology 1998;51:1369-76.
12. Covarrubias DJ, Luetmer PH, Campeau
NG. Posterior reversible encephalopathy
syndrome: prognostic utility of quantitative
diffusion-weighted MR images. AJNR Am J
Neuroradiol 2002;23(6):1038-48.
13. Provenzale JM, Petrella JR, Cruz LCH,
Wong JC, Engelter S, Barboriak DP. Quantitative
assessment of diffusion abnormalities
in posterior reversible encephalopathy syndrome.
AJNR Am J Neuroradiol 2001;22:
1455-61.
14. Cordelli DM, Masetti R, Bernardi B, et al.
Status epilepticus as a main manifestation of
posterior reversible encephalopathy syndrome
after pediatric hematopoietic stem cell
transplantation. Pediatr Blood Cancer 2012;
58(5):785-90.
15. Natsume J, Sofue A, Yamada A, Kato K.
Electroencephalographic (EEG) findings in
posterior reversible encephalopathy associated
with immunosuppressants. J Child Neurol
2006;21:620-3.
16. Lazo KG, Mandel S, Pramanik B, Lee J,
Devita M, Coven DGS. Posterior reversible
encephalopathy syndrome (PRES): a case report
and review of the literature. Pract Neurol
2016:44-7.
17. de Laat P, Te Winkel M, Devos A, Catsman-
Berrevoets C, Pieters R, van den Heuvel-
Eibrink M. Posterior reversible encephalopathy
syndrome in childhood cancer. Ann
Oncol 2011;22(2):472-8.
18. Lucchini G, Grioni D, Colombini A, et al.
Encephalopathy syndrome in children with
hemato-oncological disorders is not always
posterior and reversible. Pediatr Blood Cancer
2008;51(5):629-33.
19. Cordelli DM, Masetti R, Zama D, et al.
Etiology, characteristics and outcome of seizures
after pediatric hematopoietic stem cell
transplantation. Seizure 2014;23(2):140-5.
20. Rabinstein AA, Mandrekar J, Merrell R,
Kozak OS, Durosaro O, Fugate JE. Blood
pressure fluctuations in posterior reversible
encephalopathy syndrome. J Stroke Cerebrovasc
Dis 2012;21(4):254-8.
21. Servillo G, Bifulco F, De Robertis E, et al.
Posterior reversible encephalopathy syndrome
in Intensive Care Medicine. Intensive Care
Med 2007;33(2):230-6.
22. National High Blood Pressure Education
Program Working Group on High Blood
Pressure in Children and Adolescents. The
fourth report on the diagnosis, evaluation,
and treatment of high blood pressure in children
and adolescents. Pediatrics 2004;114(2
Suppl 4th Report):555-76.
23. Fukuyama T, Tanaka M, Nakazawa Y, et
al. Prophylactic treatment for hypertension
and seizure in a case of allogeneic hematopoietic
stem cell transplantation after posterior
reversible encephalopathy syndrome.
Pediatr Transplant 2011;15(8):E169-73.
24. Aranas RM, Prabhakaran S, Lee VH. Posterior
reversible encephalopathy syndrome
associated with hemorrhage. Neurocrit Care
2009;10(3):306-12.
25. Siegal D, Keller A, Xu W, et al. Central
nervous system complications after allogeneic
hematopoietic stem cell transplantation:
incidence, manifestations, and clinical significance.
Biol Blood Marrow Transplant 2007;
13(11):1369-79.
26. Beitinjaneh A, McKinney AM, Cao Q,
Weisdorf DJ. Toxic leukoencephalopathy following
fludarabine-associated hematopoietic
cell transplantation. Biol Blood Marrow Transplant
2011;17(3):300-8.
27. Onder AM, Lopez R, Teomete U, et al.
Posterior reversible encephalopathy syndrome
in the pediatric renal population. Pediatr
Nephrol 2007;22(11):1921-9.
28. Roth C, Ferbert A. The posterior reversible
encephalopathy syndrome: whats certain,
whats new? Pr Neurol 2011;11:136-44.
29. Antunes NL, Small TN, George D, Boulad
F, Lis E. Posterior leukoencephalopathy
syndrome may not be reversible. Pediatr
Neurol 1999;20(3):241-3.
30. Cordelli DM, Masetti R, Ricci E, et al. Life-
threatening complications of posterior reversible
encephalopathy syndrome in children.
Eur J Paediatr Neurol 2014;18(5):632-
40.
31. Lee VH, Wijdicks EF, Manno EM, Rabinstein
AA. Clinical spectrum of reversible posterior
leukoencephalopathy syndrome. Arch
Neurol 2008;65(2):205-10.
32. Noe A, Cappelli B, Biffi A, et al. High incidence
of severe cyclosporine neurotoxicity in
children affected by haemoglobinopaties undergoing
myeloablative haematopoietic stem
cell transplantation: early diagnosis and
prompt intervention ameliorates neurological
outcome. Ital J Pediatr 2010;36(1):14.
33. Thompson CB, June CH, Sullivan KM,
Thomas ED. Association between cyclosporin
neurotoxicity and hypomagnesaemia.
Lancet 1984;2(8412):1116-20.
Corrispondenza: riccardo.masetti5@unibo.it